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Abstract
Rapamycin (Rap) and its derivatives, called rapalogs, are being explored in clinical trials tar-
geting cancer and neurodegeneration. The underlying mechanisms of Rap actions, how-
ever, are not well understood. Mechanistic target of rapamycin (mTOR), a lysosome-
localized protein kinase that acts as a critical regulator of cellular growth, is believed to medi-
ate most Rap actions. Here, we identified mucolipin 1 (transient receptor potential channel
mucolipin 1 [TRPML1], also known as MCOLN1), the principle Ca2+ release channel in the
lysosome, as another direct target of Rap. Patch-clamping of isolated lysosomal mem-
branes showed that micromolar concentrations of Rap and some rapalogs activated lyso-
somal TRPML1 directly and specifically. Pharmacological inhibition or genetic inactivation
of mTOR failed to mimic the Rap effect. In vitro binding assays revealed that Rap bound
directly to purified TRPML1 proteins with a micromolar affinity. In both healthy and disease
human fibroblasts, Rap and rapalogs induced autophagic flux via nuclear translocation of
transcription factor EB (TFEB). However, such effects were abolished in TRPML1-deficient
cells or by TRPML1 inhibitors. Hence, Rap and rapalogs promote autophagy via a
TRPML1-dependent mechanism. Given the demonstrated roles of TRPML1 and TFEB in
cellular clearance, we propose that lysosomal TRPML1 may contribute a significant portion
to the in vivo neuroprotective and anti-aging effects of Rap via an augmentation of autop-
hagy and lysosomal biogenesis.
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Rapamycin (Rap) is a natural macrocyclic compound that was initially isolated from Strepto-
myces hygroscopicus as an antifungal agent [1]. Because Rap was shown to have robust immu-
nosuppressive and antiproliferative efficacy [2], Rap derivatives (rapalogs; see S1 Fig) with
improved pharmacokinetic properties have been developed in the industry, including temsiro-
limus (Tem), everolimus (Eve), deforolimus (Defo), zotarolimus (Zota), WYE-592, and ILS-
920 [3, 4]. Since 1999, Rap (brand name Sirolimus) and several rapalogs have been approved
by the United States Food and Drug Administration for clinical trials testing their ability to
target cancer cells and to alleviate metabolic and neurodegenerative diseases [3, 4]. More
recently, Rap was also shown to extend life span across diverse organisms ranging from flies to
mammals [4, 5]. Hence, elucidating the molecular mechanisms of Rap bioactivities is of great
value for both basic and clinical research.
The first identified target protein of Rap was discovered in yeast and named target of rapa-
mycin (TOR) [6, 7]. TOR, now renamed mechanistic target of rapamycin (mTOR), is a serine
and/or threonine kinase that is highly conserved in eukaryotes [6, 7]. Although multiple cellular
locations have been reported, there is now a consensus that mTOR is localized predominantly
on the membranes of lysosomes under nutrient-rich conditions [8]. In response to environmen-
tal changes, such as nutrient availability, mTOR kinase activity is switched on and off through
the formation of alternate protein complexes—mTOR complex 1 (mTORC1) and mTORC2—
and through association with and dissociation from lysosomal membranes. Known mTOR sub-
strates include, but are not limited to, UNC-5–like autophagy activating kinase (ULK1; also
known as autophagy-related protein 1 homolog), p70 ribosomal protein S6 kinase (S6K), 4E
binding protein 1 (4E-BP1), and transcription factor EB (TFEB) [9]. Rap acts as a high-affinity
(nM range) allosteric inhibitor of mTORC1 (hereafter referred to as mTOR) that blocks mTOR
substrate recruitment by binding to the FK506 binding protein (FKBP) and the rapamycin bind-
ing (FRB) domain of mTOR, forming a ternary FKBP12-Rap-mTOR complex [3, 4].
Both the anticancer and immunosuppressive effects of Rap are likely due to its inhibition of
cell proliferation via mTOR, which integrates a number of signaling pathways in the cell and
has thus emerged as a major regulator of cellular proliferation and growth [7]. However,
mTOR inhibition also induces autophagy, a lysosome-dependent cellular survival mechanism
that supplies recycled nutrients by degrading obsolete cellular components [10]. Defective
autophagy may hasten aging and enable the pathogenesis of numerous diseases, including can-
cer and neurodegenerative diseases [4]. Hence, autophagy induction caused by mTOR inhibi-
tion may also explain many of the reported effects of Rap, especially neuroprotection and anti-
aging effects [2, 11].
The basic autophagic process consists of autophagosome formation, autophagosome–lyso-
some fusion, and lysosomal degradation [12]. Nutrient insufficiency is a potent inducer of
autophagy, in which the loss of nutrients (e.g., amino acids) causes mTOR inhibition. Subse-
quently, dephosphorylation of ULK1, a major mTOR target, primes phagophore initiation
[12]. Rap can mimic the effect of starvation on ULK1-mediated autophagy induction [12].
Although all rapalogs inhibit mTOR potently, their clinical efficacies vary [13]. Rapalogs with
relatively low mTOR binding affinities (e.g., WYE-592 and ILS-920) exhibit neuroprotective
effects at least as potent as that of their counterparts with higher mTOR binding affinities [3].
Furthermore, although mTOR is inhibited much more potently by its catalytic inhibitors (e.g.
Torin-1), in vivo beneficial effects have not been observed for these potent inhibitors [14].
Hence, Rap may have other targets besides mTOR in the autophagy pathway.
Sustained autophagy requires lysosome activation, reformation, and biogenesis [12, 15, 16].
Under conditions when lysosome function is compromised, such as in neurodegenerative
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diseases and lysosome storage diseases (LSDs), it is unlikely that an increase in autophagosome
formation alone could produce beneficial effects related to cellular clearance. Nutrient starva-
tion, a physiological inducer of autophagy, promotes both autophagosome formation and lyso-
some biogenesis. Upon starvation-induced mTOR inhibition, TFEB, a key regulator of
autophagy and lysosome biogenesis [17], undergoes rapid activation via dephosphorylation
and cytosol-to-nucleus translocation [17–20]. Starvation may also activate mucolipin 1
(MCOLN1; also known as transient receptor potential channel mucolipin 1 [TRPML1]), a
lysosomal Ca2+ channel required for TFEB activation via the Ca2+-dependent phosphatase cal-
cineurin [21, 22]. Activation of TFEB, in turn, up-regulates TRPML1 expression [23]. There-
fore, TRPML1 and TFEB may constitute a positive-feedback loop that boosts lysosomal
biogenesis and autophagy under lysosomal stress conditions. Indeed, up-regulation of either
TFEB or TRPML1 has been reported to benefit several LSDs, including Pompe disease and
Niemann-Pick type C (NPC) disease, as well as common neurodegenerative diseases, includ-
ing Alzheimer disease [15, 17, 24, 25].
In the present study, we found that the TRPML1-TFEB-autophagy pathway is directly acti-
vated by Rap and some rapalogs. Employing biomolecular interaction assays and whole-endo-
lysosome electrophysiology, we demonstrated that Rap bound directly to TRPML1 and
specifically activated TRPML1 independent of mTOR.
Results
Direct activation of lysosomal TRPML1 channels by Rap
Given TRPML1’s proposed roles in lysosomal membrane trafficking and cellular clearance
[24], we used Ca2+ imaging and electrophysiological assays to screen for potential TRPML1
modulators from a list of natural products that are known to affect lysosome function or
autophagy. Whole-endolysosome recordings were performed in vacuoles that had been
enlarged with vacuolin-1 and isolated manually from enhanced green fluorescent protein
(EGFP)-TRPML1–transfected CV-1 in Origin Simian-1 (COS1) cells [26] (Fig 1A). We found
that Rap induced robust activation of whole-endolysosomal TRPML1 current (ITRPML1; Fig 1B
and 1C). The activation had a half-maximal effective concentration of 12.8 ± 1.0 μM (n = 4
patches; Fig 1C and 1D), demonstrating potency less than that of the endogenous agonist
phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) but comparable to that of the TRPML1 syn-
thetic agonist 1 (ML-SA1) [25]. Like the currents evoked by the known agonists, Rap-evoked
ITRPML1 was inhibited by TRPML1 synthetic inhibitors (ML-SIs), e.g., ML-SI3 [22] (also see
Fig 1E). On the other hand, Rap failed to affect the constitutively active mutant TRPML1 chan-
nels (TRPML1Va; Fig 1F). Furthermore, endogenous ITRPML1 was activated by Rap in wild-
type (WT) but not in TRPML1 knockout (KO) parietal cells (Fig 1G and 1H). In contrast,
whole-endolysosome ITRPML3 and ITPC2 (two-pore channel 2) were not affected by Rap (Fig
1J–1L); mild but significant activation was observed in TRPML2-expressing cells (Fig 1I and
1L). Rap also had synergistic effects on ITRPML1 with PI(3,5)P2, the endogenous agonist of
TRPML1 [27] (S1E Fig). These results suggest that Rap is a specific and robust activator of
TRPML1.
TRPML1 activation by Rap and rapalogs is independent of mTOR
Lysosome-localized mTOR is a well-established target of Rap [13], and mTOR inhibition
reportedly modulates the lysosomal TPC Na+ channel [28] and TRPML1 [29] activities. How-
ever, we found that Rap (or ML-SA1) activation of ITRPML1 occurred in the presence or
absence of ATP magnesium salt (Mg-ATP) in the cytoplasmic (bath) solution (Figs 1C, S2A–
S2C), arguing against the involvement of mTOR. As a positive control, whole-endolysosome
Lysosomal Ca2+ channel is a novel rapamycin target.
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Fig 1. Direct activation of lysosomal TRPML1 channels by Rap. (A) Whole-endolysosome recording configuration. Pipette (luminal) solution was standard Tyrode’s
solution with the pH adjusted to 4.6 to mimic the lysosomal lumen. Bath (internal) solution was a K+-based solution (140 mM K+-gluconate). Inward currents indicate
cations flowing out. (B) Representative time course of whole-endolysosome TRPML1-mediated currents (ITRPML1, open circles, at −120 mV) activated by bath application
of Rap (in μM: 1, 2, 5, 10, 20, 50). ITRPML1 was recorded from an enlarged vacuole isolated from EGFP-TRPML1–transfected COS1 cells. Currents were elicited by repeated
Lysosomal Ca2+ channel is a novel rapamycin target.
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ITPC2 was confirmed to be sensitive to Mg-ATP (S2F Fig). We further examined whether other
mTOR inhibitors, including Torin-1, a potent catalytic mTOR inhibitor that is structurally dif-
ferent from Rap (S1 Fig) [30], could activate ITRPML1. No noticeable activation was seen with
various concentrations of Torin-1 (10 μM; see Fig 2A and 2D), which abolished mTOR activity
completely in biochemical assays with an S6K phosphorylation readout (Fig 2E). These differ-
ential effects of Rap and Torin-1 suggest that Rap-induced TRPML1 activation is distinct from
its inhibitory effect on mTOR.
The TRPML1 activation effects of several commercially available mTOR-inhibiting rapalogs
(S1 Fig) were found to differ drastically (Fig 2E). Whereas Tem and Eve activated ITRPML1 readily,
albeit with slightly lower potencies than Rap (Figs 2B, 2D and S1A), activation was not seen with
Defo or Zota (Figs 2C, 2D and S1B). Furthermore, Seco-Rap, an open-ring metabolite of Rap,
failed to activate ITRPML1 (Figs 2C, 2D and S1C). This dissociation of TRPML1 activation from
mTOR suggests that Rap and rapalogs activate TRPML1 independent of mTOR inhibition.
mTOR kinase activity is not required for Rap activation of TRPML1
To further rule out mTOR involvement in Rap activation, we adopted a genetic approach to
abolish mTOR catalytic activity through the overexpression of a kinase-dead dominant-nega-
tive mutation (D2357E) of mTOR [31]. Consistent with previous reports [28, 32], Mg-ATP–
induced ITPC2 suppression was largely abrogated in COS1 cells overexpressing mTORD2357E
compared with cells transfected with WT mTOR (S2G Fig). In contrast, mTORD2357E overex-
pression did not alter Rap-induced ITRPML1 (Fig 2F and 2G). The robust stimulatory effect of
Rap on ITRPML1 was retained in cells overexpressing either a Rap-insensitive (S2035T) or a
hyperactive (L1460P) mTOR mutant [33] (S2D and S2E Fig). Furthermore, Rap also robustly
activated ITRPML1 in mTOR constitutively active (tuberous sclerosis complex 2 gene knockout
[TSC2 KO]) mouse embryonic fibroblasts (MEFs; Fig 2H and S2H Fig), as well as in mTOR-
deficient Ras-related GTP-binding protein A and B gene double KO (Rag A/B KO) MEFs (Fig
2I and S2I Fig) and p18/LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and mTOR
activator 1) gene KO human embryonic kidney 293 (HEK293) cells (Fig 2J and S2J Fig).
Hence, Rap activates TRPML1 independent of mTOR activity.
We also generated mutations at mouse TRPML1 serine (Ser) 571 and Ser 576, residues cor-
responding to the mTOR-mediated phosphorylation sites (Ser 572 and Ser 576) in the human
homolog [34]. Both nonphosphorylatable mutants (S571A/S576A) and phosphorylation-mim-
icking mutants (S571D/S576D) of TRPML1 were activated readily by Rap or ML-SA1 (S2L
Fig), further supporting the notion that Rap activation of TRPML1 is independent of mTOR
kinase activity.
Rap binds directly to TRPML1
We next performed biomolecular interaction analyses [3] to investigate the direct interaction
between Rap and TRPML1. Unlike Rap, FK506 (Tacrolimus, a Rap analog) failed to activate
voltage ramps (−120 to +120 mV; 200 ms) with a 4-s interstep interval. (C) Representative ITRPML1 by 2 μM, 5 μM, 10 μM, and 20 μM Rap (time points as in panel B).
Partial voltage protocol is shown (holding potential, 0 mV). (D) Dose-dependent activation of TRPML1 by Rap. (E) Rap-evoked ITRPML1 was blocked by coapplication of
ML-SI3, a synthetic inhibitor of TRPML1. (F) Constitutively active ITRPML1-Va was not affected by Rap. (G) Rap evoked endogenous ITRPML1 inWT parietal cells. (H) No
Rap-induced ITRPML1 was detected in TRPML1 KO parietal cells. (I) Whole-endolysosome ITRPML2 was activated by Rap in mCherry-TRPML2–transfected COS1 cells. (J)
Rap did not activate ITRPML3. (K) Rap did not produce activation of whole-endolysosome ITPC2 in EGFP-TPC2–transfected COS1 cells. (L) Summary of Rap effects on
TRPML1, 2, and 3, and TPC2. Data are presented as mean ± SEM. Dashed line indicates 1 (no change in current). Only representative data are shown in (E–K). The
individual data underlying (D) and (L) can be found in S1 Data. COS1, CV-1 in Origin Simian-1; EC50, half maximal effective concentration; EGFP, enhanced green
fluorescent protein; KO, knockout; mCherry, a monomeric red fluorescent protein; ML, TRPML; ML-SA1, TRPML1 synthetic agonist 1; ML-SI3, TRPML1 synthetic
inhibitor 3; Rap, rapamycin; TPC2, two-pore channel 2; TRPML1, transient receptor potential channel mucolipin 1; WT, wild type.
https://doi.org/10.1371/journal.pbio.3000252.g001
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TRPML1 channels (Fig 3A) and was thus used as a negative control. Immobilized FKBP12 on
biosensor chips was used as a positive control [3]. Consistent with previous studies [3], sensor-
grams displayed high-affinity binding (nM range KD) of Rap and FK506 with FKBP12 (S3C
Fig 2. Rap and rapalogs activate TRPML1 in an mTOR-independent manner. (A) Effect of Torin-1 (10 μM), a potent ATP-competitive mTOR inhibitor, on ITRPML1.
(B) Tem (10 μM) and Eve (10 μM) stimulation of ITRPML1. (C) No effects of Defo (10 μM), Zota (10 μM), and Seco-Rap (a Rap metabolite, 10 μM) on ITRPML1 measured at
−120 mV. (D) Summary of differential effects of rapalogs on ITRPML1. Data are presented as mean ± SEM. (E) Rap and rapalogs inhibited mTOR activity, which was
assayed by phosphorylation of the mTOR substrate S6K at Thr 389. (F) Rap activated ITRPML1 in cells transfected with WT mTOR (left) and a kinase-dead mTORD2357E
mutant (right). (G) mTOR mutants did not alter Rap sensitivity of ITRPML1. Data are presented as mean ± SEM. (H) Rap activated ITRPML1 in bothWT (left) and TSC2 KO
(mTOR constitutively active, right) MEF cells. Inset shows the lack of TSC2 proteins in the TSC2 KO. (I) Rap effects on ITRPML1 in RagA and B KO (mTOR deficient,
right) MEF cells. Inset shows the lack of RagA proteins in the RagA and B KO. (J) Rap activated larger endogenous ITRPML1 in p18 KO (right) compared withWT (left)
HEK293 cells. Inset shows the lack of p18 proteins in the p18 KO. Note that in p18 KO cells, endogenous TFEB was localized in the nucleus, presumably due to mTOR
deficiency (see S2K Fig), which in turn increased ITRPML1, because TRPML1 is the one of major target genes of TFEB [10]. Only representative data are presented in A–C,
F, and H–J. The individual data underlying D and G can be found in S1 Data. CTRL, control; Defo, deforolimus; Eve, everolimus; HEK293, human embryonic kidney 293
cell; KO, knockout; MEF, mouse embryonic fibroblast; mTOR, mechanistic target of rapamycin; p18, late endosomal/lysosomal adaptor, MAPK and mTOR activator 1
(LAMTOR1); Rag, Ras-related GTP-binding protein; Rap, rapamycin; Seco, seco-rapamycin; S6K, S6 kinase; Tem, temsirolimus; TFEB, transcription factor EB; Thr 389,
threonine 389; TRPML1, transient receptor potential channel mucolipin 1; TSC2, tuberous sclerosis complex 2; WT, wild type; Zota, zotarolimus.
https://doi.org/10.1371/journal.pbio.3000252.g002
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Fig 3. Rap and rapalogs bind TRPML1 in vitro. (A) Lack of FK506 effect on ITRPML1. Representative ITRPML1 was shown. (B) Rap
bound to immuno-purified EGFP-TRPML1 immobilized on Pro-A biosensors in a dose-dependent manner. (C) Dose-dependent Tem-
TRPML1 binding. (D) Weak or nonspecific binding of Zota to TRPML1. (E) Weak or nonspecific binding of FK506 to TRPML1. Panels
B–E show representative binding activity from at least 4 independent experiments. (F) Dose-dependent Rap- and rapalog-TRPML1
binding. To avoid the interference of other Rap-targeting proteins, e.g., mTOR, we subtracted Rap binding activity in nontransfected
HEK293 cells from that in EGFP-TRPML1–overexpressing cells. Data are presented as mean ± SEM (n = 4–6 independent experiments),
and the individual data can be found in S1 Data. a.u., arbitrary unit; EGFP, enhanced green fluorescent protein; FK506, tacrolimus;
HEK293, human embryonic kidney 293; mTOR, mechanistic target of rapamycin; Pro-A, protein A; Rap, rapamycin; Tem,
temsirolimus; TRPML1, transient receptor potential channel mucolipin 1; Zota, zotarolimus.
https://doi.org/10.1371/journal.pbio.3000252.g003
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and S3D Fig). EGFP-TRPML1 proteins were immuno-purified with anti–green fluorescent
protein (GFP) antibody (S3A Fig, inset) and immobilized on the protein A (Pro-A) sensor.
Compared with the FK506 controls, TRPML1 proteins showed significant Rap binding with
an estimated KD = 20.9 ± 1.8 μM (n = 6 independent experiments; Fig 3B and 3E and 3F). Con-
sistent with the electrophysiological analyses (Fig 2A–2C), Tem, but not Zota, also exhibited
specific binding responses to TRPML1 (Fig 3C and 3D and 3F). Together, these in vitro inter-
action assay results suggest direct, specific bindings of Rap and rapalogs to TRPML1. The esti-
mated in vitro binding affinity was roughly consistent with our electrophysiological results
(see Fig 1C and 1D).
Rap and/or Tem induces Ca2+-dependent TFEB nuclear translocation in
TRPML1-overexpressing HeLa cells
Recently, we showed that TRPML1 activation by ML-SAs and reactive oxygen species is suffi-
cient to activate TFEB (via nuclear translocation) and enhance autophagy in a Ca2+-dependent
but mTOR-independent manner [22]. On Henrietta Lacks (HeLa) cells stably expressing
TFEB-GFP (TFEB stable cells), we found that low micromolar concentrations of Rap failed to
induce TFEB nuclear translocation (Fig 4A and 4B). In TFEB stable cells overexpressing mono-
meric red fluorescent protein (mCherry)-TRPML1, however, Rap (5 μM) induced rapid, dra-
matic TFEB nuclear translocation (Fig 4A and 4B). Consistent with our electrophysiology data,
TRPML1-activating rapalogs, such as Tem (5 μM) and Eve (5 μM), caused TFEB nuclear trans-
location, whereas nonactivating rapalogs did not (Fig 4A and 4B and S4A Fig). Endogenous
TFEB was also activated by Rap or Tem, but not Zota, in TRPML1-overexpressing HeLa cells
(S4C Fig). Note that Tem, a synthetic Rap ester [35], was more effective than Rap in TFEB
nuclear translocation (S5B–S5E Fig), suggesting that certain chemical properties of Tem might
have made it more suitable for cell-based assays. Tem-induced TFEB activation was abolished
by coapplication of ML-SI3 (Fig 4C and 4D). Consistently, Tem failed to induce TFEB nuclear
translocation in cells transfected with TRPML1DD/KK (a channel-dead pore mutant; S4D and
S4E Fig), whereas overexpression of a constitutively active mutant of TRPML1 (TRPML1Va) led
to nuclear accumulation of TFEB (S4D and S4E Fig) in the absence of Tem. Hence, Rap and
Tem activated TFEB in cells with relatively high expression levels of TRPML1. Finally, in agree-
ment with our electrophysiology analyses (Fig 1I and 1J), Tem evoked TFEB nuclear transloca-
tion in TRPML2-transfected cells but not in TRPML3-transfected cells (Fig 4F and 4G).
Because TRPML1 is the major lysosomal Ca2+-release channel, we investigated whether
Rap- and/or Tem-induced TFEB activation was Ca2+ dependent. Application of 1,2-Bis(2-ami-
nophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM), a
membrane-permeable form of Ca2+ chelator, blocked Tem-induced TFEB activation (Fig 4E
and S4B Fig). Consistently, Tem readily increased cytosolic Ca2+ levels in HEK293 cells that
were stably expressing genetically encoded GFP- and calmodulin-based Ca2+ probe 7
(GCaMP7)-TRPML1 (S4G Fig), and the increases were blocked by ML-SI3 (S4G Fig). Tem
also significantly increased cytosolic Ca2+ levels in TRPML2-transfected HEK293 cells (S4H
Fig). Hence, consistent with the electrophysiological analyses (Fig 1I and 1J) and TFEB nuclear
translocation assays (Fig 4F and 4G), Rap and/or Tem activates TRPML1 and TRPML2 but
not TRPML3. Collectively, these results suggest that Rap and/or Tem activates TFEB via a
TRPML1/2- and Ca2+-dependent mechanism.
Rap and Tem activate TFEB through TRPML1 in human fibroblasts
Although several cell lines, such as HEK293 and HeLa cells, appeared to be “Rap-insensitive,”
i.e., they lack Rap- and/or Tem-induced TFEB activation (S4I Fig), in multiple lines ofWT
Lysosomal Ca2+ channel is a novel rapamycin target.
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human fibroblasts, 1 to 10 μM of Tem or 10 to 20 μM Rap robustly and quickly (within 1 h)
activated TFEB (Fig 5A–5C and S5A–S5E Fig). The effects of Rap and Tem on TFEB nuclear
translocation were abolished in Mucolipidosis IV (ML1−/−) human fibroblasts or by ML-SI3
(Fig 5A–5D and S5E Fig). In contrast, Torin-1–induced TFEB activation was unaffected (Fig
5A). Hence, Rap and Tem activated TFEB via TRPML1 in human fibroblasts. It is possible that
Fig 4. Rap and rapalogs induce TRPML1- and Ca2+-dependent TFEB nuclear translocation in TRPML1-overexpressing cells. (A) Rap (5 μM) and Tem (5 μM)
induced TFEB nuclear translocation in TFEB-GFP stable cells overexpressing mCherry-TRPML1 (asterisks). TFEB nuclear translocation was not seen with Zota (5 μM).
Scale bar = 10 μm. (B) Summary of rapalog effects on TFEB nuclear translocation. (C) Blockade of Tem-induced TFEB translocation by ML-SI3 (10 μM). Scale
bar = 10 μm. (D) Quantification of ML-SI3 effect. (E) BAPTA-AM (5 μM, 1 h pretreatment) blocked Tem-induced TFEB nuclear translocation. (F) Tem (5 μM) induced
TFEB nuclear translocation in TFEB-GFP stable cells overexpressing mCherry-TRPML2. Quantification is shown in the right panel. (G) The effects of Tem (5 μM, 2 h)
and ML-SA1 (5 μM, 2 h) on TFEB nuclear translocation in TFEB-GFP stable cells that were transfected with mCherry-TRPML3. Data are quantified in the left panel.
mCherry-positive cells are indicated by asterisks. Scale bar = 10 μm. Data shown in B and D–G were obtained from 30 to 40 cells from at least 3 independent experiments
and are presented as mean ± SEM. The individual data supporting B and D–G can be found in S1 Data. ���P< 0.001, one-way ANOVA. BAPTA-AM, 1,2-Bis
(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis (acetoxymethyl ester); CTRL, control; Cyt, cytoplasm; Defo, deforolimus; Eve, everolimus; GFP, green
fluorescent protein; mCh, mCherry; mCherry, monomeric red fluorescent protein; ML1, TRPML1; ML-SA1, TRPML1 synthetic agonist 1; ML-SI3, TRPML1 synthetic
inhibitor 3; Nuc, nuclear; O/E, overexpression; Rap, rapamycin; Seco, seco-rapamycin; Tem, temsirolimus; TFEB, transcription factor EB; ML1/TRPML1, transient
receptor potential channel mucolipin 1; Zota, zotarolimus.
https://doi.org/10.1371/journal.pbio.3000252.g004
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the Rap-TRPML1-TFEB pathway was “sensitized” in human fibroblasts compared with other
cell lines such as HEK cells. Notably, Tem (10 μM, 6 h) also induced dramatic TFEB nuclear
translocation in multiple disease fibroblasts, including NPC fibroblasts, Huntington disease
(HD) fibroblasts, and immortalized Duchenne Muscular Dystrophy (DMD) myoblasts (Fig
5D and 5E).
Calcineurin inhibitors, FK506 (5 μM) and cyclosporine (CsA, 10 μM) [21], reduced Tem-
induced TFEB nuclear translocation (S5D and S5E Fig), suggesting that calcineurin may be
the lysosomal Ca2+ sensor that mediates Rap activation of TFEB. TFEB nuclear translocation is
determined by its phosphorylation status [18, 19]. TFEB phosphorylation at Ser 142 and Ser
211 was reduced by Rap and/or Tem inWT human fibroblasts, and the reduction was pre-
vented by ML-SI3,ML1−/− (S7A, S7B, S7D and S7E Fig), or by coapplication of FK506 and
CsA (S7F and S7G Fig). Hence, the TRPML1-Ca2+-calcineurin pathway plays an essential role
in Rap- and/or Tem-induced TFEB activation.
Rap and Tem activate TFEB through TRPML1 to boost lysosomal
functions
We next investigated the transcriptional activity of TFEB in TRPML1 stable HEK293 cells
using a 4X-CLEAR luciferase reporter [36]. Tem (10 μM, 16 h) treatment increased 4X-
CLEAR luciferase activity by approximately 50%, and the increase was suppressed by ML-SI3
(Fig 5G). Consistently, quantitative real-time polymerase chain reaction (RT-qPCR) analyses
revealed that Tem (10 μM, 16 h) readily increased mRNA expression levels of TFEB target
genes, including those related to lysosome biogenesis, e.g., TRPML1, cathepsin D (CTSD), and
LAMP1, in a TRPML1-dependent manner (Fig 5F). Furthermore, both Rap (20 μM, 6 h) and
Tem (10 μM, 6 h) treatment significantly increased the fluorescent intensities of both Lyso-
Tracker (an assay of lysosome acidification) and Magic Red (an assay of cathepsin B activity)
inWT but not inML1-/- cells (S5F and S5G Fig). Taken together, these results suggest that Rap
and Tem activation of TRPML1 may enhance lysosomal functions, e.g., by activating TFEB.
Rap and Tem increase autophagic flux in a TRPML1-dependent manner
In HEK293 cells, Tem (10 μM) induced clear TFEB nuclear translocation, but only when
TRPML1 was overexpressed (Fig 6A). Hence, HEK293 cells are “Rap-insensitive” cells, in
which the Rap-TRPML1-TFEB pathway can be sensitized with TRPML1 overexpression. Con-
sistently, a dramatic increase in microtubule-associated proteins 1A/1B light chain 3B (LC3)-II
protein levels was induced by Tem (10 μM, 9 h) in TRPML1 stable HEK293 cells upon doxycy-
cline (Dox) induction; only mild effects were seen in noninduced cells (Fig 6B–6E).
InWT human fibroblasts in which the Rap-TRPML1-TFEB pathway is sensitized, Tem
robustly increased LC3-II protein levels (Fig 6F and 6G, S6C and S6H and S6J Fig). Blocking
Fig 5. Tem activates the endogenous TRPML1-TFEB pathway. (A) Tem (10 μM, 9 h) induced TFEB (green) nuclear translocation inWT but notML1−/−
fibroblasts. TFEB nuclear translocation was inhibited by coapplication of ML-SI3 (10 μM). Nuclei were labelled with DAPI (red, pseudo-color). Scale
bar = 10 μm. (B) Summary of Tem effects on TFEB nuclear translocation inWT andML1−/− human fibroblasts. (C) Dose-dependent and time-dependent
effects of Tem on TFEB translocation. (D) The effects of Tem (10 μM, 6 h) on cells derived from human disease tissues, e.g.,ML1−/−, NPC, HD, and DMD. (E)
Quantification of Tem effects shown in (D). Data shown in B, C, and E were obtained from more than 40 cells from at least 3 independent experiments. (F) The
effects of Tem (10 μM, 16 h) on mRNA expression levels of TRPML1, CTSD, and LAMP1 (n = 3–5 independent experiments). (G) The effects of Tem (10 μM,
16 h) on TFEB activity, measured using a 4X-CLEAR luciferase reporter (n = 4 independent experiments); Torin-1 (1 μM, 16 h) was used as a positive control.
Data shown in B, C,and E–G are presented as mean ± SEM, and the individual data can be found in S1 Data. �P< 0.05, ��P< 0.01, ���P< 0.001, one-way
ANOVA. CTRL, control; CTSD, cathepsin D; Cyt, cytoplasm; DMD, Duchenne Muscular Dystrophy; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase;
HD, Huntington disease; LAMP1, lysosome-associated membrane protein 1; ML1−/−, Mucolipidosis IV; ML-SI3, TRPML1 synthetic inhibitor 3; NPC,
Niemann-Pick type C; Nuc, nuclear; Tem, temsirolimus; TFEB, transcription factor EB; TRPML1, transient receptor potential channel mucolipin 1; WT, wild
type; 4X-CLEAR, four CLEAR elements (GTCACGTGAC) in tandem derived from LAMP1 promoter + HTK.
https://doi.org/10.1371/journal.pbio.3000252.g005
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lysosome function using the vacuolar H+-ATPase (V-ATPase) inhibitor, Bafilomycin A1 (Baf-
A1), further increased LC3-II levels (Fig 6F and S6D Fig). In contrast, the Tem effects on
LC3-II were abolished inML1-/- cells or by ML-SI3 or calcineurin inhibitors (Fig 6B–6G and
S6C, S6H, S6J and S7F Figs). Tem also markedly increased LC3-II levels in cancer cell lines
(S6E Fig). Likewise, potent ML-SA compounds had a similar effect (S6A Fig).
Likewise, Tem (10 μM, 2 h) significantly increased GFP-positive and red fluorescent pro-
tein (RFP)-positive (GFP+RFP+) puncta (autophagosome) in GFP-RFP-LC3 stable HeLa cells
overexpressed with Cyan Fluorescent Protein (CFP)-TRPML1 (S6F and S6G Fig), which was
largely diminished in the presence of ML-SI3 (S6F and S6G Fig). Sequestosome-1 (SQSTM1/
p62) is another indicator of autophagic flux [38]. Whereas short-term (3–6 h) treatment of
Tem slightly reduced p62 levels, longer (e.g., 9–16 h) treatment indeed increased p62 protein
levels in WT but not inML1-/- or ML-SI3–pretreatedWT cells (S6H–S6J Fig). The mRNA
Fig 6. Tem increases autophagic flux through TRPML1. (A) Tem (5 μM, 3 h) induced TFEB (green) nuclear translocation in TRPML1 stable cell lines (TRPML1 HEK
Tet-On) upon Dox (1 μg/ml, overnight) induction. GPN (200 μM, 2 h) was used as a positive control due to its consistent activation on TFEB in HEK cells [37]. Nuclei
were labelled with DAPI (red, pseudo-color). Scale bar = 10 μm. (B) Tem (10 μM, 9 h) dramatically increased LC3-II levels in Dox-induced cells, which was blocked by
ML-SI3 (10 μM). (C) Summary of Tem effects on LC3-II levels (normalized with GAPDH expression). (D) Dose-dependent effects of Tem (0.5, 1, 2.5, 5, and 10 μM; 9 h
treatment) on LC3-II expression levels in Dox-induced TRPML1 stable cells. (E) Quantification of dose-dependent Tem effects shown in D. (F) Tem (10 μM, 9 h) elevated
LC3-II levels inWT but notML1−/− human fibroblasts. Baf-A1 treatment increased LC3-II levels in bothWT andML1−/− cells. Tem effects inWT cells were blocked by
ML-SI3. (G) Quantification of Tem effects on LC3-II levels in fibroblasts. Data shown in C, E, and G were obtained from at least 3 independent experiments and are
presented as mean ± SEM. The individual data of C, E, and G can be found in S1 Data. �P< 0.05, ��P< 0.01, ���P< 0.001, one-way ANOVA. Baf-A1, Bafilomycin A1;
CTRL, control; Dox, doxycycline; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GPN, Glycyl-l-phenylalanine 2-naphthylamide; HEK, human embryonic kidney
293 cells; LC3-II, microtubule-associated proteins 1A/1B light chain 3B-II; ML−/−, Mucolipidosis IV; ML-SI3, TRPML1 synthetic inhibitor 3; Tem, temsirolimus; Tet-On,
Tetracycline-On; TFEB, transcription factor EB; TRPML1, transient receptor potential channel mucolipin 1; WT, wild type.
https://doi.org/10.1371/journal.pbio.3000252.g006
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expression levels of p62 were significantly increased by Tem, and the increases were blocked
by ML-SI3 (S6K Fig). Therefore, Tem may regulate both fast protein degradation and slow
gene expression of p62. Collectively, these results suggest that Tem activation of TRPML1 facil-
itates both autophagic flux and autophagosome biogenesis.
Both targets of Rap, mTOR and TRPML1, are known to converge on TFEB phosphoryla-
tion and dephosphorylation [21, 22]. To segregate these two effects, we investigated the effect
of Rap activation of TRPML1 on mTOR using other mTOR substrates, such as S6K and ULK1
[9], as the readout. For instance, mTOR-mediated phosphorylation at Ser 758 inactivates the
ULK1 complex to impede autophagy initiation [39]. TRPML1 inhibitors did not affect the
inhibitory effects of Tem on p-S6K and p-ULK1 levels (S6C and S7A–S7C Figs). In addition,
Tem effects on LC3-II levels were also preserved in 5’ adenosine monophosphate-activated
protein kinase (AMPK) α1/α2 double KO MEFs (S6B Fig). Taken together, these results sug-
gest that Rap and Tem increase autophagic flux mainly through TRPML1 activation instead of
mTOR inhibition or AMPK activation, two well-known signaling pathways that mediate
autophagy [12].
Discussion
Rap and rapalog actions have been presumed to be mediated by inhibition of mTOR [4]. For
instance, the neuroprotection and anti-aging effects of Rap have been attributed to its effects
on autophagy induction [5]. Rap induction of autophagy has thus far been attributed to
mTOR-mediated inhibition of ULK1 [4]. When mTOR is active, autophagy is inhibited by
phosphorylation of the autophagy regulatory complex containing ULK1 [7]. However, autop-
hagy induction alone is unlikely to increase autophagic flux given the severely compromised
state of lysosome functions in many neurodegenerative diseases and aging [17]. Indeed, when
lysosomes are dysfunctional, such as in various LSDs and neurodegenerative diseases,
increased autophagic induction may further burden diseased cells, worsening pathological
symptoms [17].
The current study challenges the popular presumption that mTOR is the sole Rap target in
the lysosome by demonstrating that the lysosomal Ca2+-permeable channel TRPML1 is also a
target of Rap and/or rapalogs. Rap was shown to activate TRPML1 via direct binding, indepen-
dent of its actions on mTOR. Unlike Rap-FKBP12 binding that displays a nanomolar affinity,
the Rap-TRPML1 interaction has a much lower binding affinity. However, although nM con-
centrations of Rap and rapalogs robustly block the S6K phosphorylation, complete inhibition
of 4E-BP requires much higher concentrations in normal cells (>500 nM) and certain cancer
cells (>20 μM) [40]. Furthermore, the anti-neurodegeneration and anti-aging effects of Rap
and/or rapalogs generally require higher doses of Rap, e.g., 5 to 20 μM via intraperitoneal
injection [11]. Hence, in such in vivo studies, it is possible that the Rap-TRPML1 interaction in
the micromolar range may induce lysosomal Ca2+ release and TFEB activation, especially in
the cells with higher levels of TRPML1 expression and endogenous agonists (e.g., PI(3,5)P2
and reactive oxygen species [ROS]) [22]. TFEB nuclear translocation then induces the expres-
sion of a unique set of genes involved in autophagosome and lysosome biogenesis [15],
enhancing autophagic cellular clearance [15, 17, 24, 25] (Fig 7). Our study reveals a TRPML1-
dependent mechanism that links Rap to autophagy via a transcriptional mechanism (Fig 7).
The TFEB-dependent mechanism may boost lysosome function in addition to autophagy
induction. Hence, unlike the Rap-mTOR-ULK1 pathway, the Rap-TRPML1-TFEB pathway
may boost both autophagosome and lysosome biogenesis, increasing autophagic flux and cel-
lular clearance. The effect of Rap on TFEB and autophagy is most obvious in the “sensitized”
cells, e.g., WT and disease human fibroblasts. In the “nonsensitized” cells, such as HEK293
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and HeLa cells, TRPML1 overexpression readily imparts the “sensitivity” (Fig 7). Although the
mechanisms underlying differential Rap sensitivity in various cells remain to be elucidated, the
TRPML1-TFEB pathway may play a more dominant role in the neuroprotective and anti-
aging effects of Rap than the mTOR-ULK1 pathway under stressed conditions, such as nutri-
ent deprivation or LSD, in which TRPML1 expression is elevated [23, 25], and the levels of
endogenous agonists, e.g., ROS, are increased [22].
Recent studies have suggested the existence of crosstalk mechanisms among autophagy pro-
cesses, mTOR, TFEB, and lysosomal Ca2+ [21, 41]. As both mTOR and our newly identified
Rap-TRPML1-Ca2+-calcineurin pathways converge on TFEB phosphorylation or dephosphor-
ylation, it may prove difficult to separate these 2 effects, e.g., whether the Rap-mTOR pathway
could be “sensitized” by the TRPML1-Ca2+-calcineurin pathway. However, it has been demon-
strated that TRPML1 activation and lysosomal Ca2+ release indeed increased rather than
decreased mTOR activity [21, 41–43]. In addition, Rap-mediated inhibition of mTOR, assayed
by other substrates—e.g., S6K and ULK1—is not affected by ML1 KO or inhibition. Further-
more, previous studies have revealed that both overexpression of constitutively active
TRPML1 and pharmacological activation of TRPML1 are sufficient to induce TFEB activation
without causing any inhibition of mTOR [21, 22, 41]. Therefore, the simplest interpretation to
the collective results is that Rap activates the TRPML1-TFEB pathway independent of mTOR.
Because mTOR KO may be lethal, to dissect out the contribution of TRPML1 to the in vivo
actions of Rap, it might be necessary to perform neuroprotection or anti-aging studies in
TRPML1 KO and overexpressing transgenic mice [22]. Meanwhile, it might prove helpful to
compare the in vivo efficacies of TRPML1-activating versus -nonactivating rapalogs. The
Fig 7. A working model of Rap stimulation of cellular clearance via the TRPML1-Ca2+-TFEB pathway. Rap effects are sensitive to
TRPML1 expression levels in “Rap-insensitive” cells. When TRPML1 expression is low, mTOR is in an active state in which it
phosphorylates and inactivates TFEB via cytosolic retention. Rap inhibition of mTOR is insufficient to cause TFEB nuclear translocation. In
“Rap-sensitive” cells, in which the Rap-TRPML1-TFEB pathway is sensitized, or stressed cells with up-regulated TRPML1, Rap binds and
activates TRPML1 channels, inducing substantial lysosomal Ca2+ release. Increases in perilysosomal Ca2+ levels activate Cn, causing TFEB
translocation from the cytosol to the nucleus. Activated TFEB then promotes the expression of autophagic and lysosomal genes, enhancing
the autophagic-lysosomal degradation pathway and cellular clearance. Cn, calcineurin; mTOR, mechanistic target of rapamycin; Rap,
rapamycin; TFEB, transcription factor EB; TRPML1, transient receptor potential channel mucolipin 1.
https://doi.org/10.1371/journal.pbio.3000252.g007
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hydroxyl group(s) at C40, found in Rap, Tem, and Eve, are missing in TRPML1-nonactivating
rapalogs (S1 Fig). Studying the rapalog-TRPML1 interaction may provide clues into how to
develop new rapalogs to activate endolysosomal Ca2+-permeable TRPML channels specifically.
Although Rap’s TRPML1 activation mechanism is unclear, the availability of TRPML1 and
TRPML3 cryo-electron microscopy (cryo-EM) structures [44, 45] may help to identify Rap-
TRPML1 interaction motif and/or site(s). The ML-SA1 binding pocket of TRPML1 is formed
by the protein’s pore helix 1, transmembrane S5, and transmembrane S6 [44, 45]. It remains to
be determined whether Rap also binds to this same region. Nevertheless, biochemically, the
present identification of TRPML1 as an additional Rap target, independent of mTOR, may
lead to a better mechanistic understanding of Rap effects on cellular clearance.
Materials and methods
Molecular biology
WT mTOR construct (plasmid #26603) was purchased from Addgene (Massachusetts, USA).
Additional mTOR and TRPML1 mutants were generated with a quick-change lightning site-
directed mutagenesis kit (Qiagen, Maryland, USA) according to the manufacturer’s instruc-
tions. All constructs were confirmed by DNA sequencing and western blotting.
Mammalian cell culture
TFEB-GFP stable cell line was kindly provided by Shawn M. Ferguson [19]. RagA/B KO, TSC2
KO, and theirWT control MEF cells were generous gifts from Drs. Kunliang Guan [46] and
David Kwiatkowski [47], respectively. p18/LAMTOR1 CRISPR KO cells were generated in
HEK293 cells using the CRISPR/Cas9 system. The 20-nucleotide guide sequence (50- CTGCT
ACAGCAGCGAGAACG) targeting human p18 gene was designed using the CRISPR design
tool (http://crispr.mit.edu/). The single guide RNAs (sgRNA) encoding target nucleotides were
cloned into a bicistronic expression vector, LentiCRISPR version 2 (a gift from Dr. Feng Zhang;
Addgene plasmid #52961, Massachusetts, USA) [48]. HEK293 cells were then transfected with
sgRNA-LentiCRISPR version 2 using lipofectamine 2000 (Thermo Fisher Scientific, New York,
USA) and selected with 3 μg/ml puromycin for 24 h. After single-cell clones were established,
their genomic DNAs were sequenced to confirm the intended genetic disruptions. The follow-
ing human fibroblasts were obtained from Coriell Institute (New Jersey, USA): WT (GM08399
and GM00969), ML1-/- (GM02048), NPC (GM18453), and HD (GM04281).
Unless otherwise indicated, all cell cultures were maintained in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum (sometimes tetracycline-free) at 37˚C in a
humidified 5% CO2 incubator. Cells usually were split 1 d before the experiments and reached
50% to 70% confluency at the experiment day. Cells were transfected with 1 to 4 μg plasmids
using lipofectamine 2000 (Thermo Fisher Scientific, New York, USA). Culture media were
refreshed 4 to 6 h post transfection, and cells were subject to imaging or electrophysiology 36
to 48 h after transfection. To induce TRPML1 or GCaMP7-TRPML1 expression in TRPML1
stable cell lines (TRPML1 HEK Tet-On), 1 μg/ml of Dox was added to the culture medium for
overnight.
Confocal imaging
For TFEB immunofluorescence detection, cells grown on glass coverslips were fixed with 4%
paraformaldehyde and permeabilized with 0.3% Triton X-100. They were blocked with 1%
bovine serum albumin in phosphate buffered saline (PBS). Endogenous TFEB was detected
with anti-TFEB primary antibody (1:200; Cell Signaling Technology, Massachusetts, USA) and
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antirabbit secondary antibodies conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, New
York, USA). Coverslips were mounted on slides with Fluoromount-G (Southern Biotech, Ala-
bama, USA), and images were acquired with an Olympus Spinning-Disk confocal microscope.
RNA extraction and RT-qPCR
Total RNA was extracted and purified from the cultured human fibroblasts using E.Z.N.A. HP
total RNA kit (Omega Bio-tek, Georgia, USA). The cDNA was then synthesized using a Super-
script III RT kit (Thermo Fisher Scientific, New York, USA). PCR mixture was prepared with
PowerUp SYBR green 2X master mix (Thermo Fisher Scientific, New York, USA) using the
following primers [21]: GAPDH, forward (fw): 50-tgcaccaccaactgcttagc-30, reverse (rev): 50-ggc
atggactgtggtcatgag-30; TRPML1, fw: 50-gagtgggtgcgacaagtttc-30, rev: 50-tgttctcttcccggaatgtc-30;
CTSD, fw: 50-cttcgacaacctgatgcagc-30, rev: 50-tacttggagtctgtgccacc-30; LAMP1, fw: 50-acgttacag
cgtccagctcat-30, rev: 50-tctttggagctcgcattgg-30; and p62/SQSTM1, fw: 50-gcactaccgcgatgaggac-30,
rev: 50-gcacttgtagcgggttccta-30. Real time qPCR was performed with ABI StepOnePlus Real-
Time PCR System.
Western blotting
Cells were lysed with ice-cold RIPA buffer (Boston BioProducts, Massachusetts, USA) in the
presence of 1× protease inhibitor cocktail (Sigma, Missouri, USA) and phosphatase inhibitor
cocktail 2 (Sigma, Missouri, USA), NaF (1 mM), and Na3VO4 (1 mM). Protein samples (10–
100 μg) were then loaded and separated on 4% to 12% gradient sodium dodecyl sulfate (SDS)-
polyacrylamide electrophoresis gels (Thermo Fisher Scientific, New York, USA) and trans-
ferred to polyvinylidene difluoride membranes. The membranes were blocked with 1% bovine
serum albumin or 5% milk in PBS supplemented with 0.1% Tween20 for 1 h and then incu-
bated with primary antibodies against S6K (1:1,000; Cell Signaling Technology, Massachusetts,
USA), p-S6K (1:1,000; Cell Signaling Technology, Massachusetts, USA), GAPDH (1:5,000;
Millipore, Massachusetts, USA), LC3 (1:1,000; Sigma, Missouri, USA), TFEB (1:1,000, Milli-
pore, Massachusetts, USA), pS211-TFEB (1:500; Cell Signaling Technology, Massachusetts,
USA), pS142-TFEB (1:1,000; Cell Signaling Technology, Massachusetts, USA), ULK1 (1:1,000;
Cell Signaling Technology, Massachusetts, USA), and pS757-ULK1 (equivalent to human
S758, 1:1,000; Cell Signaling Technology, Massachusetts, USA). Bound antibodies were
detected with horseradish peroxidase-conjugated antirabbit or antimouse secondary antibod-
ies (1:5,000) and enhanced chemiluminescence reagents (Thermo Fisher Scientific, New York,
USA). The total S6K, ULK1, and TFEB were reblotted in the same membranes after stripping
using a stripping buffer (Thermo Fisher Scientific, New York, USA) for 10 to 30 min. Protein
levels were quantified with ImageJ (NIH) software. The LC3-II/GAPDH, p-ULK1/ULK1, and
p-TFEB/TFEB ratios were further normalized to DMSO control ofWT cells.
Ca2+ imaging
GCaMP imaging was performed in HEK293 cells stably expressing GCaMP7-TRPML1, a lyso-
some-targeted genetically encoded Ca2+ sensor [25] or HEK293 cells overexpressing GCaMP3-
TRPML1DD/KK and mCherry-TRPML2. Fluorescence intensity at 488 nm was recorded with an
EasyRatioPro system (Photon Technology International, Inc. New Jersey, USA).
Immunopurification of EGFP-TRPML1
Nontransfected and EGFP-TRPML1–expressing HEK293 cells were lysed in an immunopre-
cipitation buffer that contained 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 2 mM CaCl2 (pH
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7.5), and 1× protease inhibitor mix. Lysates were centrifuged at 14,000g for 10 min, and super-
natants were incubated with an anti-GFP antibody (GenScript, Jiangsu, China; 1 μg per
1 × 107 cells) at 4˚C for 1 h. Pro-A/protein G plus-agarose (Santa Cruz, Shanghai, China) was
then added (10 μl per μg of antibody), and the mix was incubated at 4˚C overnight with gentle
shaking. Agarose beads were washed with the immunoprecipitation buffer 4 times, then used
in Rap binding assays.
Biomolecular interaction assay
FKBP12, a high-affinity Rap-binding protein, was used as an internal control [3]. Hexahisti-
dine (his6)-tagged FKBP12 was purified and biotinylated and then immobilized on the strepta-
vidin (SA) biosensors for 10 min [3]. Similarly, recombination TRPML1 (approximately
100 μg/ml) and HEK293 cell lysates (approximately 100 μg/ml) were immunopurified and
were immobilized onto Pro-A biosensors. The compound-protein binding was determined by
sequentially immersing individual biosensors into Rap- and/or rapalog-PBST buffer (contain-
ing PBS, 0.05% Tween 20, and 0.02% BSA) for 100 s at each concentration (1.6, 3.1, 6.3, 12.5,
25, 50, 100, and 200 μM). The compound-protein interaction was recorded and analyzed by
Octet Bio-Layer Interferometry Systems (ForteBio, Shanghai, China).
Whole-endolysosome electrophysiology
Experiments were performed in mechanically isolated endolysosomes as described previously
[22, 26, 27]. In brief, cells were treated with 1 μM vacuolin-1 overnight to increase the size of
late endosomes and lysosomes selectively [49], and TRPML2 and TRPML3 were recorded
from vacuoles enlarged with 300 nM vicenistatin overnight [50]. Unless otherwise indicated,
vacuoles were bathed continuously in an internal (cytoplasmic) solution containing 140 mM
K+-gluconate, 4 mM NaCl, 1 mM EGTA, 2 mM MgCl2, 0.39 mM CaCl2, and 20 mM HEPES
(pH adjusted with KOH to 7.2; free [Ca 2+]i approximately equal to 100 nM). The pipette
(luminal) solution contained 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
glucose, 10 mM HEPES, and 10 mM MES (pH adjusted to 4.6 or 7.4 with NaOH). The whole-
endolysosome configuration was achieved as described previously [26]. After formation of a
giga-seal between the patch pipette and an enlarged endolysosome, voltage steps of several
hundred millivolts with a millisecond duration were applied to break into the vacuolar mem-
brane [26]. All bath solutions were applied via a fast perfusion system that produced a com-
plete solution exchange within a few seconds. Data were collected via an Axopatch 2A patch
clamp amplifier, Digidata 1440, and processed with pClamp 10.0 software (Axon Instruments,
Molecular Device, California, USA). Whole-endolysosome currents were digitized at 10 kHz
and filtered at 2 kHz. All experiments were conducted at room temperature (21˚C–23˚C), and
all recordings were analyzed in pCLAMP10 (Axon Instruments, Molecular Device, California,
USA) and Origin 8.0 software.
LysoTracker staining
Lysosomal acidity was detected using LysoTracker Red DND-99 (L7528; Thermo Fisher Scien-
tific, New York, USA). Briefly, human fibroblasts were split and cultured in a 24-well dish 1 d
before the experiment. To visualize the acidic organelles, LysoTracker Red (50 nM) was added
into the cell culture medium and incubated at 37˚C for 30 min. Cells were then washed twice
with PBS and kept in PBS for imaging. Images were taken using an Olympus IX81 inverted
fluorescence microscope, and the intensity of LysoTracker was analyzed using ImageJ
software.
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4X-CLEAR luciferase assay
TFEB activity was measured in TRPML1 stable HEK293 cells using a dual-luciferase reporter
system (Promega E1910, Wisconsin, USA). Briefly, cells were cotransfected with a 4X-CLEAR
luciferase reporter (a gift from Dr. Albert La Spada; Addgene plasmid # 66800) [36] and
Renilla luciferase plasmid in a 1:20 ratio for 6 h. Cells were lysed 24 h post transfection, and
cell lysates were then transferred to a 96-well opaque plate. Luciferase activities were detected
using GloMax Microplate Luminometer (Progema, Wisconsin, USA). The activity of
4X-CLEAR luciferase was divided by that of Renilla luciferase and then normalized to the
DMSO controls.
Cathepsin B activity assay
Cathepsin B activity was measured using Magic Red Cathepsin B assay kit (ImmunoChemistry
Technologies, Minnesota, USA). Magic Red stock solution was prepared according to the
manufacturer’s instruction. Cells were incubated with Magic Red reagent (1:1,000 dilution
from stock solution) at 37˚C for 1 h and fixed by 4% PFA before imaging. Images were taken
using an Olympus IX81 inverted fluorescence microscope. Magic Red intensity was analyzed
with ImageJ software.
Reagents
Rap, Tem, and Eve were purchased from LC Laboratories (Massachusetts, USA) or MedChem-
Express (New Jersey, USA). Defo (MK-86669) and Zota (ABT-578) were purchased from Sell-
eckchem (Texas, USA). ML-SA1 was obtained from Princeton BioMolecular Research (New
Jersey, USA). ML-SI3 was custom synthesized (available upon MTA request). Seco-Rap
(148554-65-8) was from Cayman Chemical (Michigan, USA), Torin-1 was from Tocris (Min-
nesota, USA), BAPTA-AM was from Thermo Fisher (New York, USA), and vacuolin-1 was
from Calbiochem (Millipore, Massachusetts, USA).
Data analysis
Data are presented as means ± SEMs. Statistical comparisons of imaging results were per-
formed with ANOVAs. P< 0.05 was considered statistically significant.
Supporting information
S1 Fig. Chemical structures of Rap and/or rapalogs. (A) Chemical structures of Rap and
TRPML1-activating rapalogs. (B) Chemical structures of non-TRPML1–activating rapalogs.
(C, D) Structure of Seco-Rap (C) and Torin-1 (D). Note that rapalogs differ at the C40 site
(highlighted in red). (E) Synergistic effect of PI(3,5)P2 and Rap on TRPML1 activation. Rap-
activated ITRPML1 was further enhanced in the presence of 0.1 μM of PI(3,5)P2. C40, carbon 40;
PI(3,5)P2, phosphatidylinositol 3,5-bisphosphate; Rap, rapamycin; Seco, seco-rapamycin;
TRPML1, transient receptor potential channel mucolipin 1.
(PDF)
S2 Fig. Rap activation of ITRPML1 is independent of mTOR. (A) Rap activated ITRPML1 in the
presence of Mg-ATP. (B) Addition of Mg-ATP (1 mM) to the bath solution did not inhibit
Rap-evoked ITRPML1. (C) Mg-ATP also did not affect ML-SA1–induced ITRPML1. (D) Rap-acti-
vated whole-endolysosomal ITRPML1 in COS1 cells transfected with mTORS2035T. (E) Rap-acti-
vated ITRPML1 in COS1 cells transfected with mTORL1460P, a hyperactive mTOR mutant. (F) PI
(3,5)P2-induced ITPC2 was suppressed by Mg-ATP (1 mM). (G) ATP effects on ITPC2 in cells
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overexpressing WT mTOR (left) or mTORD2357E mutant (middle), and the quantification of
ATP effects (right). (H, I) Quantification of Rap effects on ITRPML1. (J) Rap effects on en-
dogenous ITRPML1 in p18WT and KO cells. (K) CRISPR-Cas9 KO of p18 caused constitutive
activation (i.e., nuclear translocation) of TFEB (lower). (L) Stimulatory effect of Rap was
retained in nonphosphorylatable TRPML1S571A/S576A (left) and phosphorylation-mimicking
TRPML1S571D/S576D (right) mutant channels. Data shown in (G–J) are presented as mean ±
SEM, and the individual data can be found in S1 Data. COS1, CV-1 in Origin Simian-1;
CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; Cas9, caspase 9; KO,
knockout; Mg-ATP, adenosine 5’-triphosphate magnesium salt; ML-SA1, TRPML1 synthetic
agonist 1; mTOR, mechanistic target of rapamycin; p18, late endosomal/lysosomal adaptor,
MAPK and MTOR activator 1; Rap, rapamycin; TFEB, transcription factor EB; WT, wild type.
(PDF)
S3 Fig. In vitro Rap-TRPML1, Rap-FKB12 and FK506-FKB12 binding assays. (A) Weak
binding of Rap with HEK293 lysates. Inset shows EGFP-TRPML1 (approximately100 kDa)
immuno-purified with an anti-GFP antibody. Averaged binding activities from 6 independent
experiments are shown. (B) Rap bound to immuno-purified EGFP-TRPML1 immobilized on
Pro-A biosensors in a dose-dependent manner. Averaged binding activities from 6 indepen-
dent experiments are shown. (C, D) Rap (C) and FK506 (D) bound to biotinylated FKBP12
(immobilized on the SA biosensors). Representative binding activity are shown. EGFP, en-
hanced green fluorescent protein; FK506, tacrolimus; FKB12, Peptidylprolyl isomerase; GFP,
green fluorescent protein; HEK293, human embryonic kidney 293 cells; Pro-A, protein A;
Rap, rapamycin; SA, streptavidin; TRPML1, transient receptor potential channel mucolipin 1.
(PDF)
S4 Fig. Tem-induced TFEB nuclear translocation is Ca2+ and TRPML dependent. (A) Eve
(5 μM, 2 h) induced TFEB nuclear translocation in TFEB-GFP stable cells overexpressing
mCherry-TRPML1 (indicated by asterisks). In contrast, no obvious TFEB nuclear transloca-
tion was seen with Defo (5 μM, 2 h), Seco-Rap (5 μM), or ML-SI3 (10 μM). Scale bar = 10 μm.
(B) BAPTA-AM (5 μM, 1 h pretreatment) blocked Tem-induced TFEB nuclear translocation.
Scale bar = 10 μm. (C) Rap (5 μM, 2 h) and Tem (5 μM), but not Zota (5 μM), induced endoge-
nous TFEB nuclear translocation in HeLa cells overexpressing mCherry-TRPML1 (indicated
by asterisks). Scale bar = 10 μm. (D) Tem showed no effect on TFEB nuclear translocation in
cells transfected with TRPML1DD/KK, a channel-dead pore mutant (upper). Overexpression of
constitutively active TRPML1Va mutant resulted in nuclear accumulation of TFEB in the
absence of Tem (lower). (E) Quantitation of TFEB nuclear translocation of (D) from 30 to 40
cells in 3 independent experiments. (F) The effects of ML-SI3 (10 μM, 1 h) pretreatment on
ML-SA1– and Torin-1–induced TFEB nuclear translocation in TFEB-GFP stable cells that
were transfected with mCherry-TRPML3 (indicated by asterisks). (G) Tem increased cytosolic
Ca2+ levels through TRPML1 activation. In cells stably expressing GCaMP7-TRPML1, Tem
(50 μM) and ML-SA1 (5 μM) increased GCaMP7 fluorescence intensity, which was blocked by
ML-SI3 (10 μM) coapplication (left). Iono (1 μM) was used as a positive control. The effects of
Tem were quantified from 9 independent experiments (right) and presented as mean ± SEM.
(H) The effects of Tem (50 μM) on cytosolic Ca2+ levels in HEK293 cells that were cotrans-
fected with mCherry-TRPML2 and GCaMP3-TRPML1DD/KK. (I) Tem (10 μM, 9 h) failed to
induce TFEB (green) nuclear translocation in HEK293 and HeLa cells. Note that Torin-1
(1 μM) induced dramatic TFEB nuclear translocation in HeLa cells but mild TFEB nuclear
translocation in HEK293 cells. Nuclei were labelled with DAPI (red, pseudo-color). Scale
bar = 10 μm. The individual data underlying (E) and (G) can be found in S1 Data. BAP-
TA-AM, 1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis (acetoxymethyl
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ester); Defo, deforolimus; Eve, everolimus; GCaMP7, GFP- and calmodulin-based Ca2+ probe
7; GFP, green fluorescent protein; HEK293, human embryonic kidney 293 cells; HeLa, Hen-
rietta Lacks cells; Iono, Ionomycin; mCherry, a monomeric red fluorescent protein; ML-SA1,
TRPML1 synthetic agonist 1; ML-SI3, TRPML1 synthetic inhibitor 3; Rap, rapamycin; Seco,
seco-rapamycin; Tem, temsirolimus; TFEB, transcription factor EB; TRPML1, transient recep-
tor potential channel mucolipin 1; Zota, zotarolimus.
(PDF)
S5 Fig. Rap- and Tem-induced TFEB nuclear translocation is TRPML1 dependent. (A)
Dose- and time-dependent effects of Tem on TFEB nuclear translocation. Scale bar = 10 μm.
(B) Rap and Tem effects on TFEB nuclear translocation in human fibroblasts. Scale bar =
10 μm. (C) Quantification of Rap and Tem effects shown in (B). (D, E) The effects of calci-
neurin inhibitors FK506 (5 μM) and CsA (10 μM) on Rap- and Tem-induced TFEB nuclear
translocation inWT andML1-/- human fibroblasts. Scale bar = 10 μm. (F) Effects of Rap
(20 μM, 6 h) and Tem (10 μM, 6 h) on LysoTracker staining inWT andML1-/- human fibro-
blasts. Torin-1 (1 μM, 6 h) was used as a control. Scale bar = 100 μm. (G) The effects of Rap
(20 μM, 6 h) and Tem (10 μM, 6 h) on Magic Red staining inWT andML1-/- cells. Torin-1
(1 μM, 6 h) was used as a control. Scale bar = 100 μm. Averaged data shown in the left panels
of (F) and (G) were from 3 independent experiments and are presented as mean ± SEM.
���P< 0.001, one-way ANOVA. The individual data underlying C, D, F, and G can be found
in S1 Data. CsA, cyclosporine A; FK506, tacrolimus; ML1−/−, Mucolipidosis IV; Rap, rapamy-
cin; Tem, temsirolimus; TFEB, transcription factor EB; TRPML1, transient receptor potential
channel mucolipin 1; WT, wild type.
(PDF)
S6 Fig. Tem increases autophagic flux through a TRPML1-dependent mechanism. (A)
TRPML1 synthetic agonists ML-SA1 (10 μM, 4 h) and ML-SA5 (1 μM, 4 h) increased LC3-II
levels inWT human fibroblasts, and the increase was suppressed by ML-SI3 (10 μM). (B) Tem
effect in AMPK α1/α2 double KO MEFs. (C) The effects of ML-SI3 (10 μM) on Tem-induced
increases in the LC3-II levels and mTOR inhibition inWT human fibroblasts. (D) The effects
of Baf-A1 (0.5 μM, 9 h) on Tem-induced LC3-II increases inWT human fibroblasts (left). (E)
The effects of TRPML1 inhibitors on the Tem (10 μM, 9 h) in M12 (prostate cancer), CN34
(breast carcinoma), and MeWo (melanoma) cells. (F) Tem (10 μM, 2 h) significantly increased
GFP+RFP+ puncta in GFP-RFP-LC3 stable HeLa cells overexpressing CFP-TRPML1. Tem
effect was inhibited by ML-SI3 (10 μM). (G) Quantification of F from more than 20 CFP-posi-
tive cells for each treatment. (H) Tem (10 μM, 9 h) increased p62 levels inWT but notML1-/-
human fibroblasts. Tem effects inWT cells were blocked by ML-SI3 (10 μM). (I) Quantifica-
tion of H. (J) Time-dependent effects of Tem (10 μM) on p62 and LC3 protein levels. (K) The
effects of Tem (10 μM, 16 h) and ML-SI3 (10 μM) on p62/SQSTM1 transcript levels, analyzed
by RT-qPCR. The black framed boxes indicate images coming from separated gel runs. Data
shown in G, I, and K were obtained from at least 3 independent experiments and are presented
as mean ± SEM. The individual data can be found in S1 Data. �P< 0.05, ��P< 0.01, ���P<
0.001, one-way ANOVA. AMPK, 5’ adenosine monophosphate-activated protein kinase; Baf-
A1, Bafilomycin A1; CFP, Cyan Fluorescent Protein; GFP, green fluorescent protein; HeLa,
Henrietta Lacks cells; KO, knockout; LC3-II, microtubule-associated proteins 1A/1B light
chain 3B-II; MEF, mouse embryonic fibroblast; ML1−/−, Mucolipidosis IV; ML-SA, TRPML1
synthetic agonist; ML-SI3, TRPML1 synthetic inhibitor 3; mTOR, mechanistic target of rapa-
mycin; p62/SQSTM1, Sequestosome-1; RFP, red fluorescent protein; RT-qPCR, quantitative
real-time polymerase chain reaction; Tem, temsirolimus; TRPML1, transient receptor
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potential channel mucolipin 1; WT, wild type.
(PDF)
S7 Fig. Rap and Tem increase autophagic flux through TRPML1-TFEB-dependent mecha-
nisms. (A) The effects of Rap, Tem, and ML-SI3 on p-ULK1 and pS142-TFEB. (B) The effects
of Tem and ML-SI3 on pS211-TFEB. (C) Quantification of p-ULK1. (D) Quantification of
Tem effect on pS211-TFEB with or without ML-SI3. (E) The effect of Tem, Rap, and Torin-1
(shown in boxes) on pS142-TFEB inWT andML1-/- human fibroblasts. (F) The effects of calci-
neurin inhibitors and Tem on pS142-TFEB. (G) Quantification of pS142-TFEB under various
treatment conditions. Data shown in C, D, and G were obtained from at least 3 independent
experiments and are presented as mean ± SEM. The individual data can be found in S1 Data.
�P< 0.05, ��P< 0.01, ���P< 0.001, one-way ANOVA. ML1−/−, Mucolipidosis IV; ML-SI3,
TRPML1 synthetic inhibitor 3; N.S., not significant; pS142-TFEB, phospho-TFEB at Ser 142;
pS211-TFEB, phospho-TFEB at Ser 211; p-ULK1, phospho-ULK1 at Ser 758; Rap, rapamycin;
Tem, temsirolimus; TFEB, transcription factor EB; TRPML1, transient receptor potential
channel mucolipin 1; WT, wild type.
(PDF)
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